Macto news continues to dominate the agenda in the early part of the week with US inflation the top item tomorrow.
If nothing else, it should be a good indicator for the Fed's interest rate mood on Wednesday.
Faron Pharma’s latest results from the BEXMAB trial in aggressive myeloid leukaemias (a rare blood cancer) showed more promising results, according to broker Peel Hunt.
Responses were noted in the two groups where previous treatments had failed, with seven out of ten of these seeing a complete response/marrow response.
MP Evans has seen forecasts for the next two years tweaked by Cavendish following the acquisition of two land packages in East Kalimantan.
Longer term the move should be beneficial, says the house broker, as free cash flow and profits accelerate over the next five years driven by scale benefits and better management of the maturing plantations.
Anglo Asian Mining has published a maiden resource estimate for its Gilar deposit in Azerbaijan of 6.10 million tonnes of mineralisation with average grades of 0.88% copper and 1.30g/t gold.
In-situ mineral resources therefore are 54,000 tonnes of copper, 255,000 ounces of gold and 46,000 tonnes of zinc.
ANGLE PLC (AIM:AGL, OTCQX:ANPCY), the liquid biopsy specialist, said researchers at the University of New Mexico used the company's Parsortix system to yeiled a potential breakthrough in the understanding of the progression of melanoma brain metastasis.
The study focused on the gene expression profile of circulating tumour cells (CTCs), which are pivotal in the development and progression of this form of cancer.
Poolbeg Pharma PLC (AIM:POLB, OTCQB:POLBF) said a poster presented by Dr Emma Searle, from The Christie Hospital, Manchester, highlighted the potential of lead asset POLB 001 as a potential therapy for cytokine release syndrome (CRS), one of the side-effects of immunotherapies.
CRS is a known risk following certain cancer treatments, such as T-cell engaging antibodies and CAR T cell therapies.
Faron Pharmaceuticals Limited (AIM:FARN, OTC:FPHAF) unveiled promising results from its BEXMAB trial at a leading medical conference, showcasing a new drug's effectiveness in treating aggressive blood cancers, and offering hope for advanced treatment options.
Researchers focused on a new drug, bexmarilimab, designed to treat aggressive forms of blood cancer, specifically Myelodysplastic Syndromes (MDS). MDS is a group of disorders caused by poorly formed or dysfunctional blood cells, often leading to severe health complications.